Table 1.
VEEV neutralizing antibody levels for pre-challenge sera in HIAF Trial 2.
| PRNT50 (Day -6) |
PRNT50 (Day 0) |
|||||
|---|---|---|---|---|---|---|
| Group description | No. positive/total tested | Percent positive (titer≥20) |
Geometric mean titer | No. positive/total tested | Percent positive (titer≥20) |
Geometric mean titer |
| WT/HIAF treated/ (challenged)a |
8/8 | 100% | 2560 | 8/8 | 100% | 2560 |
| WT/ (challenged only)a |
N.D. | N.D. | N.D. | 0/8 | 0% | 1 |
VEEV-specific antibody response was assessed by PRNT of individual sera samples in HIAF Trial 2 (described in Fig. 1B). For PRNT values that were below the limit of detection (<20), an arbitrary value of 1 was used for calculation of the geometric mean titer, presented by group. The titer is reported as the reciprocal of the serum dilution corresponding to an endpoint of 50% plaque reduction.
a
(), procedure to be performed;
b
N.D., not done.